Novartis AG (ETR:NOT)
Germany · Delayed Price · Currency is EUR | Market Cap | 258.84B +22.5% |
| Revenue (ttm) | 49.62B +2.7% |
| Net Income | 11.17B -6.6% |
| EPS | 5.79 -3.4% |
| Shares Out | n/a |
| PE Ratio | 23.18 |
| Forward PE | 17.22 |
| Dividend | 4.10 (3.01%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | 433 |
| Open | 134.28 |
| Previous Close | 135.32 |
| Day's Range | 133.50 - 136.36 |
| 52-Week Range | 103.16 - 144.12 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 27, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial numbers in USD Financial StatementsNews
Novartis’ iptacopan granted FDA orphan designation
Novartis (NVS)’ iptacopan was granted FDA orphan designation as a treatment of atypical hemolytic uremic syndrome, according to a post to the agency’s website.
CBSE Releases KVS, NVS Tier 2 Recruitment Results In Phases: Teaching, Non-Teaching Positions
CBSE Recruitment: The board further stated that results for the remaining posts are also being finalised and will be declared in phases over the next few days.
Novartis defeats UK court bid to invalidate blockbuster drug Entresto patent
Swiss drugmaker Novartis on Thursday defeated a bid to invalidate its patent for blockbuster heart drug Entresto, with London's High Court rejecting a claim by Intas Pharmaceuticals' Accord Healthca...
Drugmakers curb Swiss reimbursement applications over US pricing concerns
Drugmakers are holding back applications for health insurance coverage in Switzerland over concerns that lower prices there could affect their U.S. business under drug-pricing policies introduced by ...
Noteworthy ETF Outflows: AVSD, HSBC, NVS, MUFG
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Avantis Responsible International Equity ETF (Symbol: AVSD) where we h...
Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data
(RTTNews) - This week's biotech roundup captured a mix of regulatory wins, restructuring action, and deal momentum driving sector sentiment. FDA and EU approvals spanned oncology, vaccines and rare di...
FDA Approves Novartis' Pluvicto Combo For Metastatic Hormone-sensitive Prostate Cancer
(RTTNews) - Novartis (NVS) announced that the U.S. Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor for...
Novartis says FDA approves Pluvicto for PSMA+ metastatic prostate cancer
Novartis (NVS) announced the US Food and Drug Administration approved Pluvicto in combination with an androgen receptor pathway inhibitor for patients with prostate-specific membrane antigen-positive ...
Novartis chart may soon 'complete a well-defined bullish reversal,' Cappelleri says
The Swiss drugmaker reported earnings a few days ago and, so far, has done a good job holding near its recent highs.
3 Dividend Stocks to Buy for a Lifetime of Passive Income
Novartis is expertly handling massive patent cliffs, which speaks volumes about how resilient its business is. Abbott Laboratories has attractive long-term opportunities within its core medical device...
Swiss Market Index Rises as US-Iran Pause Lifts Sentiment, Defensive Pharma Giants Anchor Gains Monday
The Swiss Market Index rose as U.S.-Iran tensions eased, boosting European markets and lowering oil prices. Defensive stocks like Roche and Novartis led the gains amid ongoing geopolitical uncertainti...
Novartis price target raised to CHF 142 from CHF 132 at Citi
Citi analyst Graham Parry raised the firm’s price target on Novartis (NVS) to CHF 142 from CHF 132 and keeps a Buy rating on the shares.
Novartis (NVS) Q2 2026 Earnings Call Transcript
Growth drivers offset generic erosion as priority brands surge 36% in constant currency.
Novartis CEO on 2Q Profit Beat, Investing in Pipeline
Novartis reported better-than-expected sales and earnings for the second quarter, driven by strong performance from its new cancer medicines which offset declining sales of its former blockbuster drug...
Novartis (NVS) Exceeds Expectations with Strong Half-Year Results
Novartis (NVS) Exceeds Expectations with Strong Half-Year Results
Novartis CEO Vas Narasimhan on Q2 earnings beat
Novartis CEO Vas Narasimhan joins CNBC's 'Squawk on the Street' to discuss the Swiss pharmaceutical company's second-quarter earnings, M&A outlook, forward guidance, and more.
Watch CNBC's full interview with Novartis CEO Vas Narasimhan
Novartis CEO Vas Narasimhan joins CNBC's 'Squawk on the Street' to discuss the Swiss pharmaceutical company's second-quarter earnings, M&A outlook, forward guidance, and more.
Novartis (NVS) Returned to Sales Growth in Q2, but the Patent-Cliff Math Still Runs the Story
Novartis AG (NVS) gave investors a better quarter in the three months ended June 30, 2026, but not a clean... The post Novartis (NVS) Returned to Sales Growth in Q2, but the Patent-Cliff Math Still Ru...
Novartis Q2 Earnings Call Highlights
Novartis NYSE: NVS said it returned to sales growth in the second quarter of 2026, supported by strong gains across priority medicines and launches, while reaffirming its full-year outlook despite con...
Q2 Earnings Pick Up Steam: GM, MMM, DHI & More
GM, MMM, NVS, NOC, HAS and DHI all outperformed expectations on their quarterly reports this morning.
Novartis Bounds For Buy Point. Why Shares Are On The Rise.
Novartis stock jumped early Tuesday on better-than-expected second-quarter metrics, partially driven by Cosentyx.
Novartis AG Earnings Call Transcript: Q2 2026
Q2 2026 saw 1% net sales growth and flat core operating income, driven by strong performance in key brands and launches, offsetting generic erosion. Full-year guidance is reaffirmed, with growth drivers showing robust momentum and multiple pivotal pipeline readouts expected in H2.
Novartis AG Quarterly report: Q2 2026
Novartis AG has published its Q2 2026 quarterly earnings report on July 21, 2026.
Novartis AG Slides: Q2 2026
Novartis AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 21, 2026.